试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-06
DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
编号:NCT05496595登记状态:提前终止企业 / 申办者:DynamiCure Biotechnology
药物 / 成分:DCBY02
登记的停止原因(原文):Review of Data, and our other compound is a better option
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-05
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
编号:NCT02013167登记状态:提前终止企业 / 申办者:Amgen
药物 / 成分:Blinatumomab、Standard of Care Chemotherapy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-05
Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn
编号:NCT02261883登记状态:提前终止企业 / 申办者:United Therapeutics
药物 / 成分:IV Remodulin、Placebo
登记的停止原因(原文):Sponsor Decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-05
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
编号:NCT02723006登记状态:提前终止企业 / 申办者:Millennium Pharmaceuticals, Inc.
药物 / 成分:TAK-580、TAK-202、vedolizumab、nivolumab
登记的停止原因(原文):Business decision: Protocol efficacy futility met
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-05
The Effects of Nicotinamide Riboside Supplementation on Brain NAD+/NADH Ratio and Bioenergetics
编号:NCT03151707登记状态:提前终止企业 / 申办者:Mclean Hospital
药物 / 成分:Nicotinamide Riboside
登记的停止原因(原文):Lack of funding and appropriate staff
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-05
Botulinum for Chronic Exertional Compartment Syndrome
编号:NCT03339921登记状态:提前终止企业 / 申办者:375th Medical Group, Scott Air Force Base
药物 / 成分:Botulinum toxin injections for chronic compartment syndrome、surgical fasciotomy for chronic compartment syndrome
登记的停止原因(原文):This study is being closed because it is unworkable.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-05
Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
编号:NCT03341962登记状态:提前终止企业 / 申办者:Immunic AG
药物 / 成分:IMU-838、Placebo
登记的停止原因(原文):Considering the efficacy results of the induction phase (allowed use of corticosteroids as concomitant medication) in the study population and since IMU-838 did not show superiority over placebo, the OLE was prematurely closed by the sponsor.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-05
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
编号:NCT03709082登记状态:提前终止企业 / 申办者:University of Kansas Medical Center
药物 / 成分:Palbociclib 75mg、Letrozole 2.5mg、T-DM1、Palbociclib 100mg
登记的停止原因(原文):Low accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-05
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
编号:NCT04816214登记状态:提前终止企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:Capmatinib、Osimertinib、Pemetrexed、Cisplatin
登记的停止原因(原文):Novartis decided to terminate the study based on a business consideration and not related with any safety concerns. Randomized part was not initiated
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-05
The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers
编号:NCT05095311登记状态:提前终止企业 / 申办者:Indiana University
药物 / 成分:Cetirizine HCl、Placebo
登记的停止原因(原文):The recruited population was no longer made available to participate in the study.
查看官方原始记录 ↗